$VXRT News

Last published 1w ago

1w agoVXRTVaxart, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoVXRTVaxart Provides Business Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswireTopline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027 Expanded intellectual property portfolio with new European patent
2w agoVXRTVaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ETGlobeNewswireCompany to report third quarter 2026 financial results on November 5 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range
3w agoVXRT HUM VIKVaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of DirectorsGlobeNewswireBoard-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart,
1mo agoVXRTVaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge ModelGlobeNewswireSecond-generation oral mucosal vaccine candidate (VXA-H5-02) induced robust cross-neutralizing antibodies, significantly reduced viral load, and completely protected against lethal clade 2.3.4.4b viral challenge SOUTH
2mo agoVXRTVaxart to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery
2mo agoVXRTVaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine TechnologyGlobeNewswireKEY HIGHLIGHTS:• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart's oral recombinant
3mo agoVXRTVaxart Provides Business Update and Reports Second Quarter 2026 Financial ResultsGlobeNewswireReported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of
3mo agoVXRTVaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ETGlobeNewswireCompany to report second quarter 2026 financial results on August 6 SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range
3mo agoVXRTVaxart to Participate in BTIG Biotechnology Conference 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery
3mo agoVXRTVaxart Announces Results of Annual Meeting of StockholdersGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill
4mo agoVXRTVaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 VaccineGlobeNewswireNo vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT)
4mo agoVXRTVaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance EnhancementsGlobeNewswireCompany to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees Stockholder Group Withdraws Director Nominations SOUTH SAN FRANCISCO, Calif.,
4mo agoVXRTVaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAYGlobeNewswireDetails Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Growth Dissident
4mo agoVXRTVaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine TrialGlobeNewswireLatest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of Key Trial Results SOUTH
4mo agoVXRTVaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual MeetingGlobeNewswireUrges Stockholders to Vote "FOR" ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 16, 2026
5mo agoVXRTVaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech ForumGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery
5mo agoVXRTVaxart to Participate in BTIG Infectious Disease Day 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery
5mo agoVXRTVaxart Urges Shareholders to Vote "FOR" ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAYGlobeNewswireMails Letter to Shareholders Detailing Strength of the Board's Nominees and Momentum in Advancing Vaxart's Value Creation Strategy Reinforces that the Dissident's Nominees Have No Relevant Biotechnology or Public
5mo agoVXRTVaxart Files Definitive Proxy Statement and Mails Letter to ShareholdersGlobeNewswireEmphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing Vaxart's Highly
5mo agoVXRTVaxart Files Preliminary Proxy Statement and Issues Open Letter to ShareholdersGlobeNewswireCompany is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit
6mo agoVXRTVaxart Provides Business Update and Reports First Quarter 2026 Financial ResultsGlobeNewswireTopline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second quarter of 2027
6mo agoVXRTVaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ETGlobeNewswireCompany to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) today announced that members of the Company's senior management
6mo agoVXRTVaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of DirectorsGlobeNewswireAppointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a
6mo agoVXRTVaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park CapitalGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral vaccines based on its
8mo agoVXRTVaxart Provides Business Update and Reports Full Year 2025 Financial ResultsGlobeNewswireTopline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was
8mo agoVXRTVaxart to Host Upcoming Conference CallsGlobeNewswireFull year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026
8mo agoVXRTVaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today
8mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsGood afternoon, everyone. I'm Gil Bash, and I'm the host of this session for the BioInnovation Forum that is sponsored by FinPartners and hosted by One Business World. I thank you for joining us today. Earlier this morni
8mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsHello, how to reduce the diagnostic heredity of millions of women in the world who suffer of endometriosis. How to go from 10 years of heredity on average to only 10 days. I am Marie-Hélène Coste, senior partner at FINE
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsWelcome to the Global Bioinnovation Forum, Shaping the Future of Health, taking place during J.P. Morgan Health Conference. Today's session, Unlocking Hidden Value, a new secondary market for late-stage rare disease ther
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsHello, everyone, and welcome to this session of the Global Bionovation Forum during JPM, hosted in partnership with One Business World. I'm Danny Sudwitz, Associate Partner at Finn Partners, and I'm delighted to introduc
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsWelcome, everyone. I'm Fern Lazar, and I'm delighted to welcome all of you to today's session of the Global Bioinnovation Forum. We've had an exciting week of innovative companies, and today's session is going to be one
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsHello, everyone, and welcome to the 2026 Global BioInnovation Forum. as you know this forum brings together leaders who are reshaping how health innovation moves from discovery to real world impact across research instit
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsHello everyone, I'm Danny Sudwitz from Finn Partners and together with One Business World, it's my pleasure to welcome you all to this session of the Global Bioinnovation Forum during JPM. I'm especially looking forward
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsHello, everyone. It's David Perry from FinPartners. Thank you for joining us today at the BioInnovation Forum. So for this session, we're going to be diving into the challenge that sits at the very heart of patient outco
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsHello, everyone. I'm David Carey of Finn Partners, and joining me today is Dr. Yeho Yalkunen, CEO of Farron Pharmaceuticals. Farron is a clinical stage biopharmaceutical company at the forefront of a clever approach to c
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsHello, everyone, and welcome to the Global BioInnovation Forum. I'm Ellie Hansen, a partner at FINN, and I'm thrilled to introduce this session on nano-amorphous minerals. I'm joined by Eden Ben, the CEO of Amorphical. E
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsGood morning, everyone. It's a pleasure to continue the conversation. Just a few moments ago, I was speaking about healing the sick care system. and how we need to learn to collaborate, to weigh into the problems that ar
9mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsHello, everybody, and welcome to the 2026 Global Bioinnovation Forum. My name is Erica Olenski, and I'm a vice president at Finn Partners. The Global Bioinnovation Forum brings together leaders who are redefining how hea
10mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsThanks to all of you for joining us at the Global BioInnovation Forum during JPMorgan Week. I'm Steve Lowe, and I'm the CEO of Vaxart, which is a clinical stage biotechnology company developing a range of oral recombinan
10mo agoVXRTEarnings Call - VAXART INCEarnings Call TranscriptsWelcome, everyone. Welcome to the BioInnovation Forum. I want to thank particularly One Business World and colleagues at FinPartners who have made this session possible. Throughout the day, you'll be hearing from some of
10mo agoVXRTVaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their InfantsGlobeNewswireVaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive
10mo agoVXRTVaxart to Participate in the Global BioInnovation Forum on January 13, 2026GlobeNewswireSOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart or "the Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its
12mo agoVXRTVaxart Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswireEntered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of
1y agoVXRTVaxart to Host Upcoming Conference CallsGlobeNewswireThird quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) --
1y agoVXRTVaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary
1y agoVXRTVaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on
1y agoVXRTVaxart Announces Withdrawal of Reverse Stock Split ProposalGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based
1y agoVXRTConcerned Vaxart Stockholders Respond to Inadequate Governance AnnouncementsGlobeNewswireBelieve Elevating W. Mark Watson – who Received only 56% of Votes Cast at Last Annual Meeting – to Lead Independent Director Fails to Deliver Real Reform Reiterate Intent to Vote Against Reverse Stock Split at September